2. Signaling Pathways
  3. Immunology/Inflammation
  4. FAP

FAP

Fibroblast activation protein

Fibroblast activation protein (FAP) is a cell-surface serine protease that acts on various hormones and extracellular matrix components. FAP is highly upregulated in a wide variety of cancers, and is often used as a marker for pro-tumorigenic stroma.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-173319
    FAP-IN-5
    		Inhibitor
    FAP-IN-5 (Compound 4a) is an FAP inhibitor with an IC50 of 1.7 nM. FAP-IN-5 can be used in the research of tumor positron emission tomography (PET) imaging.
    FAP-IN-5
  • HY-174421
    FAPI-JNU
    		Ligand
    FAPI-JNU is a molecule targeting fibroblast activation protein (FAP). FAPI-JNU specifically binds to FAP highly expressed in the tumor microenvironment, and uses radionuclides [68Ga]Ga or [177Lu]Lu to achieve tumor imaging diagnosis. [177Lu]Lu−FAPI−JNU can effectively target and inhibit tumor growth in tumor-bearing mice. FAPI-JNU is promising for research of FAP-positive tumors (such as various solid tumors).
    FAPI-JNU
  • HY-146181
    FSDD1I
    FSDD1I is an albumin-binding fibroblast activation protein (FAP) ligand. FSDD1I can be labeled with 68Ga and 177Lu for single photon emission computed tomography (SPECT) imaging.
    FSDD1I
  • HY-103323
    Fas C-Terminal Tripeptide
    		Inhibitor
    Fas C-Terminal Tripeptide is a C-terminal tripeptide of Fas. Fas C-Terminal Tripeptide shows the inhibitory effect on Fas/FAP-1 binding.
    Fas C-Terminal Tripeptide
  • HY-P3441
    3BP-4089
    3BP-4089 is a highly potent fibroblast activation protein (FAP)-targeting peptide for theranostics. 3BP-4089 is often coupled with radionuclides for tumor diagnosis and research.
    3BP-4089
  • HY-177083
    Faridoxorubicin
    		Substrate
    Faridoxorubicin (AVA-6000) is a prodrug targeting fibroblast activation protein α (FAPα). Faridoxorubicin releases active doxorubicin through FAPα-mediated cleavage, enhancing intratumoral drug exposure and reducing cardiac toxicity. Faridoxorubicin is promising for research of solid tumors (e.g., colorectal cancer liver metastasis).
    Faridoxorubicin
  • HY-148361
    Fluorogen binding modulator-1
    Fluorogen binding modulator-1 (PubChem SID 125240934) is a fluorogen activating protein (FAP)-fluorogen binding modulator with -log EC50s of 6.61 and 6.37 for AM2.2-β2AR and AM2.2-GPR32, respectively.
    Fluorogen binding modulator-1
  • HY-P991087
    RO7122290
    		Agonist
    RO7122290 is a bispecific fusion protein carrying a split trimeric 4-1BB (CD137) ligand and a fibroblast activation protein α (FAP) binding site. O7122290 is a FAP-α-targeted 4-1BB agonist that costimulates T cells for improved tumor cell killing in FAP-expressing tumors.
    RO7122290
  • HY-170779
    DOTA-NI-FAPI-04
    		Inhibitor
    DOTA-NI-FAPI-04 is a FAP inhibitor (IC50 = 7.44 nM). By integrating FAP targeting with hypoxia-sensitive groups (nitroimidazole), DOTA-NI-FAPI-04 significantly enhances tumor uptake and retention capabilities. DOTA-NI-FAPI-04 chelates metallic isotopes (such as 68Ga and 177Lu) through DOTA to produce radioactive probes ([68Ga]Ga/DOTA-NI-FAPI-04 and [177Lu]Lu/DOTA-NI-FAPI-04), which can be used for research in tumor diagnostics and therapeutic agents. DOTA-NI-FAPI-04 holds dual targeting potential in the fields of cancer imaging, tumor microenvironment analysis, and radionuclide therapy, particularly suitable for scenarios where the tumor stroma and hypoxic regions synergistically interact.
    DOTA-NI-FAPI-04
  • HY-146182
    FSDD3I
    FSDD3I is an albumin-binding fibroblast activation protein (FAP) ligand. FSDD3I can be labeled with 68Ga and 177Lu for single photon emission computed tomography (SPECT) imaging.
    FSDD3I
  • HY-175353
    TriOncoFAP-GlyPro-MMAE
    TriOncoFAP-GlyPro-MMAE is a small molecule drug conjugate (SMDC) targeting fibroblast activation protein (FAP) with an IC50 of 13 pmol/L. TriOncoFAP-GlyPro-MMAE combines a FAP-targeting ligand (TriOnco), a cleavable glycine-proline linker, and a cytotoxic payload (MMAE).
    TriOncoFAP-GlyPro-MMAE
  • HY-P3392
    Zilganersen
    Zilganersen (ION373) is a glial fibrillary acidic protein (GFAP) inhibitor, an antisense oligonucleotide. Zilganersen can be used in Alexander disease (AxD) research.
    Zilganersen
  • HY-164364B
    DOTAGA.(SA.FAPi)2 analogue TFA
    		Inhibitor
    DOTAGA.(SA.FAPi)2 analogue TFA is a DOTAGA.(SA.FAPi)2 TFA (HY-164364A) analogue, in which the ligand and the chelator are identical to those of DOTAGA.(SA.FAPi)2 TFA. DOTAGA.(SA.FAPi)2 TFA is a potent dimeric fibroblast-activation protein inhibitor (FAPi).
    DOTAGA.(SA.FAPi)2 analogue TFA
  • HY-163079
    AlF-PD-FAPI
    AlF-PD-FAPI has affinity for FAP , with the IC50 of 0.13 nM, and shows a specific uptake, high internalized fraction, and low cellular efflux in vitro. AlF-PD-FAPI can be used as FAP-targeting tracer.
    AlF-PD-FAPI
  • HY-W668749
    3BP-3580
    		Inhibitor
    3BP-3580 is a fibroblast activation protein (FAP) inhibitor (pIC50: 8.6), and can be used for cancer research.
    3BP-3580
Cat. No. Product Name / Synonyms Application Reactivity